Laboratory operations note: beckman-coulter-products-in-the-clinical-laboratory-a-6step-checklist-for-a-126

You've got an urgent lab need. The current analyzer is down for the third time this quarter. The test menu is expanding and the deadline just got pulled forward. Or a contract is expiring and you need options in days, not months. In each case, the question is the same: which Beckman Coulter product fits this lab, and can we prove it fits?

I coordinate urgent equipment verifications for clinical laboratories—that's what I've spent the last seven years doing. During that time I've handled more than 200 expedited evaluations, including same-week turnarounds for labs that were days from losing out-of-pocket referral business. Missing one of those deadlines would have meant real consequences: delayed patient testing, strained referral relationships, even penalty clauses in service agreements. This checklist is the one I use when the timeline is short and the decision has to survive scrutiny from procurement, compliance, and the medical director.

Six steps, roughly 25 minutes of focused work. Every step ends with a checkpoint you can verify on official channels. Let's go.

The 25-Minute Checklist

Step 1: Write Down the Exact Assays, Not the Product Names

"We need a Beckman Coulter analyzer" sounds specific until you realize Beckman Coulter products span multiple families: clinical chemistry (AU series), immunoassay (Access series), hematology (DxH), flow cytometry (CytoFLEX), and life-sciences automation for NGS workflows. Each family has its own test menu, its own software, its own consumables. Choose the family first; narrow the model later.

Start with the assays. List every test that needs to run on Day One—troponin I, TSH, hCG, hemoglobin A1c, everything the lab actually bills for. Then list the tests you expect to add in the next 18 months. That second list matters more than you'd think. Labs that skip it end up with an analyzer that's perfect for today and insufficient for next year.

Checkpoint: One page confirming (a) the assays required at go-live and (b) expected peak daily volume. No product research until that page exists.

Step 2: Pull the Current Access 2 Test List

If the Access 2 immunoassay analyzer is on your shortlist, its test menu is the first thing to verify. The Access 2 test list is broad for routine testing: cardiac markers (troponin I, CK-MB), thyroid function (TSH, FT4, FT3, T3, T4), reproductive hormones (hCG, FSH, LH, prolactin), tumor markers (AFP, CEA, PSA, CA 125, CA 19-9), and anemia markers (ferritin, B12, folate).

Here's what most people miss: the menu varies by region and by software version. The test list on the manufacturer's US website isn't necessarily what's approved in the EU or APAC. And it changes over time—what was listed in 2023 may not be available in 2025.

One more thing: read the intended-use statements, not just the assay names. A "research use only" (RUO) assay is different from an in-vitro diagnostic (IVD) assay. Running an RUO assay in a patient-reporting workflow is a compliance problem that no analyzer upgrade can fix.

Checkpoint: Download the official Beckman Coulter Access 2 test list from the manufacturer's website, date it, and cross-check every assay from Step 1. If one is missing, the Access 2 is not your instrument—regardless of price.

Step 3: Match Throughput to Peak-Day Reality

The Access 2 does roughly 100 tests per hour. The Access DxI 800 runs around 400 per hour. If your lab clears 150 billable tests on a Monday morning, the Access 2 might work. If you're processing 500, you'll be running overtime every week.

I still kick myself for a decision I made in 2022. I signed off on a lower-throughput system because I used monthly averages instead of peak-day numbers. Average days don't exist in clinical labs. We spent six months eating an afternoon backlog before agreeing to reroute heavy volume to another platform. The analyzer itself was fine; the sizing was wrong.

Checkpoint: Calculate peak-day volume using the busiest three days of the last three months. Size for that number at 80% utilization, not 100%. The buffer is your margin for error.

Step 4: Verify Regulatory Status for Today, Not Last Year

As of May 2025, immunoassay analyzers marketed in the EU need to comply with the In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) and carry appropriate CE marking. In the US, FDA clearance or approval status matters. These aren't just paperwork details—they determine whether you can legally run patient samples in your jurisdiction.

Don't hold me to the exact IVDR transition schedule, though. Those dates have moved multiple times since 2022 and may shift again. The point isn't to memorize the deadline; it's to verify current status before signing anything.

Checkpoint: Email your Beckman Coulter representative and ask for written confirmation of the regulatory status of each instrument and assay SKU you plan to order. If the reply doesn't match your assumptions, stop and reassess.

Step 5: Build the Three-Year Total Cost Table

The instrument price is the least useful number on the quote. Total cost of ownership includes the instrument, reagents, calibrators, quality controls, service contract, training, freight, installation, and—the underrated one—consumable wastage during ramp-up.

There's something satisfying about watching a well-structured cost table expose a bad assumption. In March 2024, I sat with a hospital lab coordinator who was 36 hours from signing a lease for an analyzer that "saved" $4,000 on the purchase price. Her three-year cost table showed that saving vanished in Year One because of reagent pricing and a mandatory quarterly service visit. She switched to a different configuration and netted roughly $7,300 over the contract term.

Checkpoint: A cost table comparing at least two platforms across instrument, reagents, service, consumables, and training/installation. No table, no signature.

Step 6: Confirm Documentation and Aftermarket Support

Beckman Coulter's documentation—user manuals, product catalogs, assay instructions for use—is solid, but you need to confirm it covers your exact configuration. Ask for the documentation list at the quoting stage, not after purchase. Three things to check:

• Operator's manual for the specific instrument model and software version
• Instructions for use for every assay kit in your proposed panel
• Service response time in your region—and whether parts are stocked locally

Oh, and ask who trains your team. Some installations include on-site training; some offer only e-learning. For a busy lab, that difference can push go-live back by weeks.

Checkpoint: Documentation list received, training plan confirmed in writing, and parts inventory location identified. If any of these is missing, you're not done.

Where This Checklist Breaks Down

To be fair, this checklist assumes you're purchasing a new, full system. It doesn't cover refurbished or second-hand equipment, where the verification process is a different, much deeper animal—budget extra time for that path.

Three mistakes I see most often:

1. Trusting the Access 2 test list from a blog or forum. Test menus change, and regional approvals differ. A post from 2023 may have been accurate then; it might be wrong now. Use the manufacturer's current documentation.
2. Skipping the regulatory check because "everyone knows it's approved." Not every SKU of every test kit is approved in every jurisdiction. I've seen a lab purchase a perfectly good analyzer, then discover the specific troponin kit wasn't cleared for their country. That's a delay you can't rush past.
3. Forgetting the clinical context that connects labs to other departments. Clinical laboratories that support nuclear medicine rely on precise diagnostic results. Thyroid function and tumor marker results from your immunoassay analyzer often determine whether a patient proceeds to a nuclear medicine procedure like radioiodine therapy. In that chain, an unverified assay menu isn't an inconvenience; it's a patient-safety concern.

Another caution from a recent project: the installation timeline is the most underestimated variable. Last November, the hardware arrived on time, but third-party network validation took an extra 10 days because security approvals hadn't been planned. The lab ran parallel systems in the interim. Not ideal, but workable—still, it cost time and goodwill. Add a week of buffer to your installation calendar and protect it like a commitment.

Granted, the fundamentals haven't changed: matching the test menu to patient needs and verifying regulatory status will always matter. What has changed is the execution. As of 2025, most manufacturers offer digital documentation portals, remote service diagnostics, and online training. Five years ago, those were luxuries. Now they're standard—and worth verifying before you sign, not after.

This same discipline extends beyond the diagnostic instrument. When a clinical team is preparing patient-ready equipment—for example, teaching someone how to use a nebulizer before discharge—the rule is identical: rely on the current official instructions, not a colleague's memory of how it used to be done. The right device, the right protocol, the right training. The fundamentals don't change; the details do.

This was accurate as of May 2025. IVDR transition dates, test menus, and product configurations change fast, so verify current status on the manufacturer's official channels before committing.